- Home
- NXRT vs TRVI Comparison
NXRT vs TRVI Comparison
Compare NXRT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXRT
- TRVI
- Stock Information
- Founded
- NXRT 2014
- TRVI 2011
- Country
- NXRT United States
- TRVI United States
- Employees
- NXRT N/A
- TRVI N/A
- Industry
- NXRT Real Estate Investment Trusts
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- NXRT Real Estate
- TRVI Health Care
- Exchange
- NXRT Nasdaq
- TRVI Nasdaq
- Market Cap
- NXRT 859.4M
- TRVI 725.7M
- IPO Year
- NXRT N/A
- TRVI 2019
- Fundamental
- Price
- NXRT $34.89
- TRVI $7.59
- Analyst Decision
- NXRT Hold
- TRVI Strong Buy
- Analyst Count
- NXRT 6
- TRVI 9
- Target Price
- NXRT $41.88
- TRVI $19.94
- AVG Volume (30 Days)
- NXRT 158.5K
- TRVI 1.6M
- Earning Date
- NXRT 07-29-2025
- TRVI 08-07-2025
- Dividend Yield
- NXRT 5.88%
- TRVI N/A
- EPS Growth
- NXRT N/A
- TRVI N/A
- EPS
- NXRT N/A
- TRVI N/A
- Revenue
- NXRT $255,529,000.00
- TRVI N/A
- Revenue This Year
- NXRT N/A
- TRVI N/A
- Revenue Next Year
- NXRT $5.28
- TRVI N/A
- P/E Ratio
- NXRT N/A
- TRVI N/A
- Revenue Growth
- NXRT N/A
- TRVI N/A
- 52 Week Low
- NXRT $30.98
- TRVI $2.36
- 52 Week High
- NXRT $48.37
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- NXRT 55.99
- TRVI 61.46
- Support Level
- NXRT $33.58
- TRVI $6.71
- Resistance Level
- NXRT $34.88
- TRVI $7.19
- Average True Range (ATR)
- NXRT 0.69
- TRVI 0.34
- MACD
- NXRT 0.13
- TRVI 0.09
- Stochastic Oscillator
- NXRT 83.83
- TRVI 77.95
About NXRT NexPoint Residential Trust Inc.
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.